Hormonal contraception and mental health: a narrative review of screening, monitoring, and patient-centered care for family physicians - Top-Institutions - MDSpire

Hormonal contraception and mental health: a narrative review of screening, monitoring, and patient-centered care for family physicians

  • By

  • Abdul Rehman Zia Zaidi

  • Hiba Elhassan

  • Amina Mariam Syed

  • Noor Waseem

  • Anush Muhammed

  • Laila Fida

  • Sidrah Fathima

  • Ismat Taha

  • Gazal Tannous

  • Shazia Irshad

  • Baraa Alghalyini

  • July 8, 2026

  • 0 min

Share

Top Institutions in Family Medicine

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts General Hospital and Brigham and Women’s Hospital (Mass General Brigham)
    Massachusetts General Hospital and Brigham and Women’s Hospital (Mass General Brigham)

    Boston, Massachusetts

    Key Differentiators

    • Psychiatry
    • Obstetrics & Gynecology

  • #2

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, California

    Key Differentiators

    • Psychiatry
    • Women's Health

  • #3

    HER Salt Lake
    HER Salt Lake

    Salt Lake City, Utah

    Key Differentiators

    • Reproductive Health

Original Source(s)

Hormonal contraception and mental health: a narrative review of screening, monitoring, and patient-centered care for family physicians

  • by Abdul Rehman Zia Zaidi, Hiba Elhassan, Amina Mariam Syed, Noor Waseem, Anush Muhammed, Laila Fida, Sidrah Fathima, Ismat Taha, Gazal Tannous, Shazia Irshad, Baraa Alghalyini

  • July 8, 2026

Related Content

Top 10 Growing Metro Areas With Active HPSAs

These 10 metropolitan areas reported population gains and active federal shortage area designations identified in census and health care workforce data.

Superficial heat therapy in women’s health

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.